dna double helix icon

Get information about cystinosis, including genetic variations, potential ocular complications, and care strategies for cystinosis patients

bottle icon

Learn about CYSTARAN® (CYSTEAMINE OPHTHALMIC SOLUTION) 0.44%, a cystine-depleting therapy indicated for the treatment of corneal cystine crystal accumulation in patients with cystinosis2

pie chart icon

Review CYSTARAN’s efficacy data in clinical studies, and see examples of how treatment with CYSTARAN successfully reduced corneal crystal density in affected eyes2-4

prescription icon

Access ordering information, learn what support programs are available for your cystinosis patients, and find options for how you can get in touch with us

child receiving eye exam

Resources about cystinosis and treatment with CYSTARAN are available for your practice.

Download copies here

References: 1. Gahl WA, Balog JZ, Kleta R. Nephropathic Cystinosis in Adults: Natural History and Effects of Oral Cysteamine Therapy. Ann Intern Med. 2007;147:242-250 2. CYSTARAN [prescribing information]. Gaithersburg, MD: Leadiant Biosciences, Inc.; Current approved PI. 3. Data on File. Leadiant Biosciences, Inc. 4. Gahl WA, Kuehl EM, Iwata F, Lindblad A, Kaiser-Kupfer MI. Corneal Crystals in Nephropathic Cystinosis: Natural History and Treatment with Cysteamine Eyedrops. Molec Genet Metab. 2000;71:100-120.

minus icon

INDICATION & IMPORTANT SAFETY INFORMATION

CYSTARAN® (CYSTEAMINE OPHTHALMIC SOLUTION) 0.44% is a cystine-depleting agent indicated for the treatment of corneal cystine crystal accumulation in patients with cystinosis.

IMPORTANT SAFETY INFORMATION

  • To minimize contaminating the dropper tip and solution, care should be taken not to touch the eyelids or surrounding areas with the dropper tip of the bottle. Keep bottle tightly closed when not in use.
  • There have been reports of benign intracranial hypertension (or pseudotumor cerebri) associated with oral cysteamine treatment that has resolved with the addition of diuretic therapy. There have also been reports associated with ophthalmic use of cysteamine; however, all of these patients were on concurrent oral cysteamine.
  • CYSTARAN contains benzalkonium chloride, which may be absorbed by soft contact lenses. Contact lenses should be removed prior to application of solution and may be reinserted 15 minutes following its administration.
  • CYSTARAN is for topical ophthalmic use only.
  • The most frequently reported ocular adverse reactions occurring in ≥ 10% of patients were sensitivity to light, redness, and eye pain/irritation, headache and visual field defects.

Please refer to CYSTARAN’s full Prescribing Information, available here.

plus icon

INDICATION & IMPORTANT SAFETY INFORMATION

CYSTARAN® (CYSTEAMINE OPHTHALMIC SOLUTION) 0.44% is a cystine-depleting agent indicated for the treatment of corneal cystine crystal accumulation in patients with cystinosis.